Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2026 08:14 ET | Source: Robbins Geller Rudman & Dowd LLP

Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action filed by Robbins Geller Rudman & Dowd LLP

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
March 22, 2026 14:45 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR DEADLINE: Soleno Therapeutics Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
March 18, 2026 14:45 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR DEADLINE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
March 11, 2026 16:10 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR NOTICE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
March 06, 2026 20:00 ET | Source: Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Soleno Therapeutics, Inc., Announces Opportunity for Investors with Substantial Losses to Lead Soleno Class Action Lawsuit

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.